

Press Release

Biofrontera to Present at the Canaccord Genuity Annual Growth Conference

Leverkusen, Germany, July 25, 2016 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced that Dr. Hermann Lübbert, the Company's Chief Executive Officer, is scheduled to present at the Canaccord Genuity Annual Growth Conference, being held August 10 – 11, 2016 in Boston.

Details for the presentation are as follows:

Date: Wednesday, August 10, 2016
Time: 11:00AM EST
Room: The Vancouver Room

A live-streaming webcast will be available at <http://wsw.com/webcast/canaccord23/b8f.de> and will be published on the Company's website shortly after the conference.

-Ends-

Enquiries, please contact: Biofrontera AG +49 (0) 214 87 63 2 0
Thomas Schaffer, Chief Financial Officer press@biofrontera.com

IR Germany: Brainwell Asset Solutions +49 (0) 152 08931514
Jürgen Benker

IR UK: Seton Services +44(0) 20 7729 0805
Toni Vallen

IR and PR US: The Ruth Group
IR: Lee Roth / Tram Bui +1 646-536-7012 / 7035
PR: Kirsten Thomas +1 508-280-6592

About Biofrontera

Biofrontera Group (FSE: B8F, ISIN DE0006046113) **Biofrontera** is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for the care and treatment of skin diseases. Biofrontera's lead product is Ameluz[®], a prescription drug which was initially approved and marketed in Europe and is now also approved in the U.S. in combination with its medical lamp BF-RhodoLED[®] for photodynamic therapy (PDT) treatment (light therapy) of mild and moderate actinic keratosis, a precursor to squamous cell carcinoma. Biofrontera is the first German pharmaceutical start-up company to obtain centralized EU and now U.S. approval for a medical device/drug it has developed itself.

The company also markets the Belixos[®] dermatological range of cosmetics. Belixos[®] products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos[®]

Press release

Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All Belixos® products are available in Europe through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

For more information, visit www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.